Publicaciones en colaboración con investigadores/as de Vancouver General Hospital (11)

2023

  1. Defining textbook outcome for selective internal radiation therapy of hepatocellular carcinoma: an international expert study

    European Journal of Nuclear Medicine and Molecular Imaging, Vol. 50, Núm. 3, pp. 921-928

2021

  1. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

    Future Oncology, Vol. 17, Núm. 16, pp. 1987-2003

  2. Establishing the injury severity of subaxial cervical spine trauma validating the hierarchical nature of the AO spine subaxial cervical spine injury classification system

    Spine, Vol. 46, Núm. 10, pp. 649-657

  3. Machine learning automatically detects COVID-19 using chest CTs in a large multicenter cohort

    European Radiology, Vol. 31, Núm. 11, pp. 8775-8785

  4. Regional and experiential differences in surgeon preference for the treatment of cervical facet injuries: a case study survey with the AO Spine Cervical Classification Validation Group

    European Spine Journal, Vol. 30, Núm. 2, pp. 517-523

2017

  1. Adverse event management in patients with relapsed and refractory multiple myeloma taking pomalidomide plus low-dose dexamethasone: A pooled analysis

    European Journal of Haematology, Vol. 99, Núm. 3, pp. 199-206

2015

  1. Cytogenetics and long-term survival of patients with refractory or relapsed and refractory multiple myeloma treated with pomalidomide and low-dose dexamethasone

    Haematologica, Vol. 100, Núm. 10, pp. 1327-1333

  2. Health-RELATED quality of life from the MM-003 trial of pomalidomide plus LOW-Dose dexamethasone VERSUS HIGH-DOSE dexamethasone in relapsed and/or refractory multiple myeloma

    Haematologica, Vol. 100, Núm. 2, pp. 63-67

  3. Impact of prior treatment and depth of response on survival in MM-003, a randomized phase 3 study comparing pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed/refractory multiple myeloma

    Haematologica, Vol. 100, Núm. 10, pp. 1334-1339

  4. Pomalidomide and Low-Dose Dexamethasone Improves Health-Related Quality of Life and Prolongs Time to Worsening in Relapsed/Refractory Patients With Multiple Myeloma Enrolled in the MM-003 Randomized Phase III Trial

    Clinical Lymphoma, Myeloma and Leukemia, Vol. 15, Núm. 9, pp. 519-530

2013

  1. Phase Ib study of panobinostat and bortezomib in relapsed or relapsed and refractory multiple myeloma

    Journal of Clinical Oncology